+ Watch IBB
on My Watchlist
Exchange Traded Funds
no end to the drop in site
Time to buy, short term oversold, is or very close to the bottom (near term), should go up for next 1-2 months
Perhaps the correction is over.
This is a healthcare/biotech ETF that has gotten alot of positive press lately. It is also a sector that should grow.
Science and drug development are not doing well, but biotech and life sciences companies are on a tear!
Affordable Care Act aka... (ObamaCare)
This is my first CAP and IBB did well yday
Biotech is a safety net for now until energy cost catches up to demand,
Bio tech will continue to lead the market
This is my signal to start focusing on a shorting strategy. The biobubble will not go on forever (though it could take another year or two).
Biotechs are strong this year.
Playing individual biotech stocks is risky business. This is probably the least risky way to play the sector without taking a chance of waking up one morning to see the company's drug was rejected and opens down 50%+ on an FDA rejection.
Price action here just looks off.
My choices in Biotech are an absolute disaster. Nonetheless, I realize that the sector has some wonderful successes and the needs of the boomer generation plus some "newly discovered" illnesses require new medicines. That makes Biotech a sector to have a presence in.Porte is our resident expert in this area and I am choosing this at his suggestion. It is worth noting that the only Biotech firms that have ever rewarded me - on CAPS or RL - are the ones that Porte has suggested to me. His suggestions are enough for me to add this to CAPS if not to add RL funds to.
The age is finally right
Betting to outperform the 500 this leg down.
loading up on biotech
I don't dislike biotech (alliterative double negative for you). However, I am willing to say that there are more bad biotech companies than good. Unfortunately, an ETF is going to have both the good and the bad so I'm going to say that a better way to play the industry is to do some extra research and find out what's actually going to work (though I may have an advantage here cuz I'm living on a campus where some of the best biotech research is being conducted)
Biotech poised for excellent returns when the market rebounds
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions